(Q38100037)

28 August 2017

title

A global regulatory science agenda for vaccines (English)

1 reference

28 August 2017

Lindsay Elmgren

1

1 reference

28 August 2017

Xuguang Li

2

1 reference

28 August 2017

Carolyn Wilson

3

1 reference

28 August 2017

Robert Ball

4

1 reference

28 August 2017

Junzhi Wang

5

1 reference

28 August 2017

Klaus Cichutek

6

1 reference

28 August 2017

Michael Pfleiderer

7

1 reference

28 August 2017

Atsushi Kato

8

1 reference

28 August 2017

Marco Cavaleri

9

1 reference

28 August 2017

James Southern

10

1 reference

28 August 2017

Teeranart Jivapaisarnpong

11

1 reference

28 August 2017

Philip Minor

12

1 reference

28 August 2017

Elwyn Griffiths

13

1 reference

28 August 2017

Yeowon Sohn

14

1 reference

28 August 2017

David Wood

15

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31 Suppl 2

1 reference

28 August 2017

page(s)

B163-75

1 reference

Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Safety and effectiveness of a 2009 H1N1 vaccine in Beijing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Real-time vaccine safety surveillance for the early detection of adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Quality by design for biopharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Challenges to licensure of enterovirus 71 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Recombinant protein vaccines produced in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

NMR detection and characterization of sialylated glycoproteins and cell surface polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

An unbiased approach for analysis of protein glycosylation and application to influenza vaccine hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Proteomics-based characterization of hemagglutinins in different strains of influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Use of DOP-PCR in Non-Specific Virus Detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Analysis of porcine circovirus type 1 detected in Rotarix vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Investigation of porcine circovirus contamination in human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Potency control of diphtheria component in adsorbed vaccines by in vitro neutralization tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Herd immunity and herd effect: new insights and definitions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

7 January 2021

Catching a Moving Target

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Interindividual variations in the efficacy and toxicity of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Resurgent diphtheria--are we safe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Vaccinomics: current findings, challenges and novel approaches for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Evaluating the safety of new vaccines: summary of a workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Rapid Emergence of Free-Riding Behavior in New Pediatric Immunization Programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Use abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Relative incidence estimation from case series for vaccine safety evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Statistical assessment of the association between vaccination and rare adverse events post-licensure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Control without separate controls: evaluation of vaccine safety using case-only methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.117

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.10.117

1 reference

28 August 2017

1 reference